NASDAQ:NKTR

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Retrieved on: 
Thursday, May 2, 2024
Nektar, NKTR, Nektar Therapeutics, Therapy, Home page, SAN, PIN

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through June 9, 2024.
  • To access the conference call, please pre-register at Nektar Earnings Call Registration .

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Friday, March 22, 2024
SAN, Conference, Q&A, NKTR, Nektar Therapeutics, Therapy, Nektar

SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.

Key Points: 
  • SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 28, 2024.

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
SAN, Nektar, Q&A, Therapy, NKTR, Nektar Therapeutics, Conference

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 5, 2024.

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

Retrieved on: 
Monday, February 26, 2024
SAN, Home page, Nektar, Therapy, NKTR, PIN, Nektar Therapeutics

SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through April 4, 2024.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Retrieved on: 
Wednesday, January 3, 2024
NKTR, Q&A, Conference, Webcast, SAN

SAN FRANCISCO, Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m. Pacific Time.

Key Points: 
  • SAN FRANCISCO, Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m. Pacific Time.
  • The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until February 9, 2024.

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Retrieved on: 
Tuesday, October 31, 2023
Nektar, Home page, Nektar Therapeutics, Therapy, NKTR, PIN, SAN, Cryptocurrency

SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through December 8, 2023.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

Retrieved on: 
Friday, October 13, 2023
Congress, Senior, NKTR, Alopecia areata, European Academy of Management, George Washington University School of Engineering and Applied Science, Development, Journal of the European Academy of Dermatology and Venereology, DLQI, Atopic dermatitis, Outline of health sciences, Contact dermatitis, Nektar, Psoriasis Area and Severity Index, Pharmacodynamics, Maintenance, SAN, AD, EASI, BSA, Patient, NRS, Nektar Therapeutics, Body surface area, Pharmaceutical industry, Regulatory T cell, Dermatology, Venereology

SAN FRANCISCO, Oct. 13, 2023  /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress. These data were presented by Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis in a late-breaking oral presentation.

Key Points: 
  • "Data from this presentation demonstrate consistent benefit with REZPEG across multiple clinician and patient-reported outcomes, which were maintained through 36 weeks after treatment ended," said Dr. Jonathan Silverberg.
  • "The sustained post-treatment benefit observed with REZPEG has the potential to alter the need for frequent maintenance dosing for patients with atopic dermatitis.
  • Based on these data, the company is initiating two Phase 2 studies in atopic dermatitis and in alopecia areata.
  • Highlight of the new patient-reported outcomes for the Phase 1b study in atopic dermatitis presented at EADV 2023 for the first time:

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Retrieved on: 
Monday, October 2, 2023
Nektar, Medical school, Naval Medical Research Center, University, Senior, NKTR, Safety, Efficacy, University School, Nektar Therapeutics, MT, Atopic dermatitis, Washington University School of Medicine, Alopecia areata, University of Washington School of Medicine, Development, Journal of the European Academy of Dermatology and Venereology, Duke University School of Medicine, Patient, SAN, Randomness, Conjugation, University of Rochester Medical Center, Science, University of Bonn, Therapy, Abstract, Queen's University, Treatment, Education, Pharmaceutical industry, Vaccine, PLLC, Dermatology, Regulatory T cell, Venereology, Northwestern University, Medicine

SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin. REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin.
  • REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.
  • "The presentations highlight the momentum and strength of our REZPEG program and, in particular, its potential as a remittive therapy for patients with atopic dermatitis.
  • Sinai, New York, NY, United States; 6Skin Sciences, PLLC, Louisville, KY, United States; 7Rodgers Dermatology, Frisco, TX, United States; 8Nektar Therapeutics, San Francisco, CA, United States; 9Eli Lilly and Company, Indianapolis, IN, United States.

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Wednesday, September 13, 2023
Alopecia areata, Nektar, Nektar Therapeutics, Patient, Pharmacokinetics, DLQI, BSA, Therapy, Atopic dermatitis, NKTR, Week, EASI, Safety, Pharmaceutical industry, Regulatory T cell

SAN FRANCISCO, Sept. 13, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study. Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis.

Key Points: 
  • Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis.
  • The company is presenting the new Phase 1b clinical efficacy endpoints for rezpegaldesleukin at its investor and analyst event today.
  • The double-blind, randomized, placebo-controlled Phase 1b study of rezpegaldesleukin in atopic dermatitis evaluated safety, tolerability, and pharmacokinetics over a 12-week induction treatment period.
  • Highlights of final efficacy endpoints for the Phase 1b study in atopic dermatitis:

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

Retrieved on: 
Wednesday, September 6, 2023
George Washington University School of Medicine & Health Sciences, Nektar, Indiana University, NKTR, Contact dermatitis, Nektar Therapeutics, Foreign, Commonwealth and Development Office, EST, Atopic dermatitis, PST, Assistant, PIN, Patient, SAN, Outline of health sciences, Therapy, Pharmaceutical industry, Veterinary medicine, Dermatology, Regulatory T cell

To access the conference call, please pre-register at Nektar Earnings Call Registration .

Key Points: 
  • To access the conference call, please pre-register at Nektar Earnings Call Registration .
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.
  • Investors and analysts can also view slides and listen to the live audio webcast of the presentation here .
  • The event will also be available for replay through October 13, 2023 on Nektar's website: www.nektar.com .